AstraZeneca to resume vaccine trials after ‘potentially unexplained illness’ prompted pause

By Zach Halaschak

Published September 12, 2020 3:35pm ET

Add Washington Examiner on Google

AstraZeneca to resume vaccine trials after ‘potentially unexplained illness’ prompted pause — A lab technician working a bottle containing for COVID-19 vaccine testing at Chula Vaccine Research Center, run by Chulalongkorn University in Bangkok, Thailand, Monday, May 25, 2020. Thai health officials said that scientists in Thailand have had promising results in testing a COVID-19 vaccine candidate on mice, and have begun testing on monkeys. | (Sakchai Lalit/AP)

AstraZeneca announced that it was restarting phase three coronavirus vaccine trials after they were paused when a participant became ill.

The pharmaceutical giant announced the resumption on Saturday after the trials were put on hold on Sunday. The patient in question, a woman, was from the United Kingdom and reportedly suffered a rare spinal cord injury.

Print subscriber? Click here to login/register your account

Digital subscriber? Click here to login/register your account.

Full midterm coverage.Deeper analysis.

Get unlimited access to Washington Examiner's reporting, expert analysis, and coverage of the midterm elections.

Get Unlimited Access

Cancel anytime.

Tag:

COVID-19 Pharmaceutical Industry Science United Kingdom Vaccines